OpenOnco · Treatment Plan

Treatment plan — Chronic Myeloid Leukemia

PLAN-VAR-CML-ORGAN-V1 · v1 · 2026-05-12

Patient

VAR-CML-ORGAN · Algorithm: ALGO-CML-1L

DiagnosisChronic Myeloid Leukemia

MOH / ICD-10C92.1

ICD-O-39863/3; C42.1

Etiological driver

Etiological driver · etiologically_driven archetype

Chronic Myeloid Leukemia

BCR-ABL1 fusion arising from t(9;22)(q34;q11.2) (Philadelphia chromosome) in 100% — defining + targetable driver
p210 (Major BCR breakpoint, e13a2 / e14a2): classic CML (>95%)
p190 (minor BCR, e1a2): more often Ph+ ALL, occasionally lymphoid-blast-phase CML
p230 (micro BCR, e19a2): rare, indolent neutrophilic CML
Sporadic; rare environmental association (ionizing radiation)

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-CML-1L-IMATINIB

Regimen

Imatinib (CML chronic phase 1L)

Drugs + NSZU

Imatinib (DRUG-IMATINIB) 400 mg PO once daily with food + large glass of water · continuous, lifelong (or until durable deep molecular response permits TFR attempt per ELN 2020 criteria) · PO ✓ NSZU covered

Reason

Primary current-line option selected by ALGO-CML-1L at step 4.

Other current-line alternatives (1 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-CML-1L-2GEN-TKI

Regimen

2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chronic phase 1L for high-risk / younger seeking TFR

Drugs + NSZU

Dasatinib (DRUG-DASATINIB) 100 mg PO once daily — DEFAULT for low-CV-risk; AVOID if pulmonary disease · continuous; lifelong unless TFR achieved · PO ✓ NSZU covered
Nilotinib (DRUG-NILOTINIB) 300 mg PO BID on empty stomach (≥1 h before / ≥2 h after meals) — DEFAULT for low-CV-risk + no pancreatitis history; AVOID if CV disease, DM, hyperlipidemia · continuous · PO ✓ NSZU covered
Bosutinib (DRUG-BOSUTINIB) 400 mg PO once daily with food — for patients with CV comorbidity precluding nilotinib AND pulmonary precluding dasatinib · continuous · PO ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-BCR-ABL-JAK2	BCR-ABL + JAK2 + CALR + MPL	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-BM-ASPIRATE	Bone Marrow Aspirate	Critical	histology	—	all tracks
TEST-BM-TREPHINE	Bone Marrow Trephine	Critical	histology	—	all tracks
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	all tracks
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	all tracks
TEST-FISH-PANEL	FISH (Fluorescence In Situ Hybridization)	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-FLOW-CYTOMETRY	Flow Cytometry	Critical	histology	CSD Lab ✓ (code TBC)	all tracks
TEST-HBV-SEROLOGY	Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs)	Critical	lab	—	all tracks
TEST-HCV-ANTIBODY	HCV Antibody	Critical	lab	—	all tracks
TEST-KARYOTYPE	Karyotype	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-LDH	Lactate Dehydrogenase	Critical	lab	—	all tracks
TEST-LFT	Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin)	Critical	lab	—	all tracks
TEST-PREGNANCY	Beta-HCG	Critical	lab	—	all tracks
TEST-ECHO	Echocardiography	Standard	imaging	—	aggressive

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

CML high-risk by ELTS (EUTOS Long-Term Survival score) — favors 2nd-generation TKI (nilotinib / dasatinib / bosutinib) over imatinib for faster deep molecular response and improved long-term outcomesRF-CML-HIGH-RISK-ELTS
CML patient with comorbidity excluding specific 2nd-gen TKIs: significant cardiovascular disease (PAOD, prior MI/stroke, uncontrolled HTN — avoid nilotinib/ponatinib), pulmonary disease (COPD, prior pleural disease — avoid dasatinib), severe GI disease (avoid bosutinib), pancreatitis history (avoid nilotinib)RF-CML-ORGAN-DYSFUNCTION
CML with T315I gatekeeper mutation in the BCR-ABL1 kinase domain — resistant to all 1st/2nd-gen TKIs; requires ponatinib or asciminib (STAMP)RF-CML-T315I-MUTATION
CML in accelerated or blast phase: ≥10% blasts in PB or BM (accelerated), ≥20% blasts (blast phase), or extramedullary blasts. Treatment intent shifts from chronic-phase TKI to acute-leukemia-style induction + alloHCT.RF-CML-TRANSFORMATION-PROGRESSION
CML chronic phase with Hasford (EURO) high risk — supports 2nd-generation TKI 1L (dasatinib / nilotinib / bosutinib) over imatinib; comparable rationale to Sokal-highRF-HASFORD-HIGH
CML chronic phase with Sokal high risk — supports 2nd-generation TKI 1L (dasatinib / nilotinib / bosutinib) over imatinib for faster MMR/MR4.5 and improved long-term cumulative incidence of progressionRF-SOKAL-HIGH

CONTRA-AGGRESSIVE

Hard contraindications to escalation

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-CML-1L-IMATINIB)

Do not skip baseline BCR-ABL1 quantitative PCR — this is baseline for milestone monitoring.
Do not skip pre-TKI HBV screening — HBV reactivation on TKI has been described in cases.
Do not skip the fertility discussion in young patients — TKI safety during pregnancy is limited; interferon-α — alternative at conception.
Do not prescribe without food + a large glass of water — GI intolerance on empty stomach.
Do not repeat imatinib 400 mg on failure — switch per ELN criteria (3 mo / 6 mo / 12 mo) to a 2nd-gen TKI.
Do not start a TFR attempt without ≥3 years of TKI + sustained MR4.5 ≥2 years + qPCR monitoring q1-2mo after stopping.

Aggressive plan (IND-CML-1L-2GEN-TKI)

Do not prescribe nilotinib without baseline CV evaluation + ECG + lipid panel + glucose — boxed QT warning + cumulative vascular toxicity.
Do not prescribe dasatinib to patients with pulmonary comorbidity / prior pleural effusion — risk of severe effusion.
Do not prescribe bosutinib to patients with IBD / severe diarrhea history — diarrhea ~70% risk.
Do not skip pre-TKI HBV screening.
Do not skip the fertility discussion; TKI safety during pregnancy is limited.
Do not start without food for bosutinib (with food); STRICTLY on empty stomach for nilotinib (≥1h before / ≥2h after).

MDT brief

Discussion questions (1, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist

MDT talk tree (2 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (1)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-CML-COMORBIDITY-COMPLEX, RF-CML-FRAILTY-AGE, RF-CML-HIGH-RISK-ELTS, RF-CML-ORGAN-DYSFUNCTION, RF-CML-T315I-MUTATION, RF-CML-TRANSFORMATION-PROGRESSION, RF-HASFORD-HIGH, RF-SOKAL-HIGH

Technical MDT skill metadata (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ELN-CML-2020: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020)
SRC-ESMO-CML-2017: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
SRC-IRIS-OBRIEN-2003: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003)
SRC-NCCN-MPN-2025: NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms (v.X.2025)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-12.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT03459534	A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	PHASE3	RECRUITING	Il-Yang Pharm. Co., Ltd.	UA	—
NCT07071155	Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia	EARLY_PHASE1	RECRUITING	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	—	Small N (<50) Single country
NCT03964506	Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant	EARLY_PHASE1	RECRUITING	Omar Aljitawi	—	Small N (<50) Single country
NCT05143840	Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase	PHASE2	RECRUITING	Augusta University	—	Single country
NCT04888741	Methods of T Cell Depletion Trial (MoTD)	PHASE2	RECRUITING	University of Birmingham	—	Single country
NCT07046078	Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer	PHASE2	RECRUITING	Fred Hutchinson Cancer Center	—	Small N (<50) Single country
NCT03533816	Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide	PHASE1	RECRUITING	University of Kansas Medical Center	—	Phase 1 only Small N (<50) Single country
NCT04708054	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	PHASE2 / PHASE3	RECRUITING	M.D. Anderson Cancer Center	—	Surrogate endpoint only Single country
NCT04588922	Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML	PHASE1 / PHASE2	RECRUITING	Sellas Life Sciences Group	—	Surrogate endpoint only
NCT01890486	The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen	N/A	RECRUITING	Wake Forest University Health Sciences	—	Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Imatinib (CML chronic phase 1L) (REG-IMATINIB-CML)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan 2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chronic phase 1L for high-risk / younger seeking TFR (REG-2GEN-TKI-CML)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs UA site available — verify enrollment status with site	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07071155 Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03964506 Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05143840 Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04888741 Methods of T Cell Depletion Trial (MoTD) No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03533816 Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04708054 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-12.

plan_id: PLAN-VAR-CML-ORGAN-V1 | version: 1 | generated: 2026-05-12T18:41:26.363369+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.